Analysis
Lycia Therapeutics set terms for its US IPO, offering 14.7 million shares priced between $16 and $18 to raise up to $264.6 million, which would value the company at up to $937.7 million, according to a report carried by 979 WEVE. The South San Francisco company plans to list on Nasdaq under the ticker LYCA, with Jefferies, TD Cowen, Evercore ISI and Guggenheim Securities as joint book-running managers.
Lycia was founded by Carolyn Bertozzi, who won the Nobel Prize in Chemistry, and is developing drugs for autoimmune, inflammatory and allergic diseases. Its most advanced program, LCA-0061, is still in an early-stage trial for food allergy -- the IPO prices the company years before any pivotal clinical readout, a risk profile typical of early-stage biotech listings but one investors are pricing more conservatively than in prior cycles.
A sub-$1B target in a biotech-led IPO market
A target valuation under $1 billion for a Nobel-laureate-founded drug developer is a modest number by the standards of past biotech IPO cycles, when scientific pedigree alone could command richer multiples. It's consistent with what Pulse has tracked across 2026's IPO pipeline more broadly: biotech has been carrying the market while megacap tech listings wait on the sidelines, with day-one pops concentrated in clinical-stage names rather than the large tech floats that typically dominate IPO headlines.
Lycia's filing lands alongside a cluster of other biotech S-1 and S-1/A activity -- BioAtla and Actuate Therapeutics among the names with recent SEC filings -- suggesting underwriters are treating this as a window worth filling with clinical-stage names while it's open, rather than a one-off. The four-bank underwriting syndicate on a raise under $300 million is relatively heavy, a sign banks are spreading distribution risk rather than betting any single lead underwriter can fully place the deal alone.
What the terms don't yet tell us: a price range is not a final price, and biotech IPOs have priced below range, at range and well above range in 2026 depending on the week's broader risk appetite -- Lycia's actual valuation won't be set until the deal prices, expected in the days after this filing.